Biotech Values

[Titan V]

NVS—Why This Heart Drug Could Be a $5B Blockbuster
https://www.biospace.com/article/around-the-web/why-this-heart-drug-could-be-a-5b-blockbuster-for-novartis/

ZURICH (Reuters) - A Novartis executive said the Swiss company’s heart failure medicine Entresto could be used more widely in future, potentially making it a blockbuster drug with revenue potential of $4 billion to $5 billion a year.

Entresto, introduced in 2015, got off to a slow start but brought in $507 million in revenue last year, just surpassing Novartis’s target of half a billion dollars and beating some analysts’ predictions.

Paul Hudson, head of the Swiss drugmaker’s pharmaceuticals unit, told Reuters in an interview that Entresto has the potential for more than $3 billion annual sales in its current usage, for reduced ejection fraction heart failure in patients whose heart muscles do not contract effectively.